EUVIMEDEUVIMED entdecken
Open Access

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights

Georgios Mangioris iD, Sean J Pittock iD, Binxia Yang, James P Fryer, William S Harmsen, Divyanshu Dubey iD, Eoin P Flanagan iD, Sebastian A Lopez-Chiriboga iD, Andrew McKeon iD, John R Mills, Ivana Vodopivec, W Oliver Tobin iD und 3 weitere

Annals of Neurology · 2024-10 · 96 (4) · 704-714

DOI: 10.1002/ana.27024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 19.07.2024. Verfasst von Georgios Mangioris und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Central Nervous System Diseases, Cytokines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the cerebrospinal fluid (CSF) cytokine/chemokine profile of central nervous system (CNS) neurosarcoidosis (NS), and its utility in differential diagnosis, treatment, and prognostication.

Methods

In this case–control study, we validated 17 cytokines/chemokines (interleukin [IL]‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17A, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and tumor necrosis factor [TNF]‐alpha) in a multiplexed automated immunoassay system (ELLA; Bio‐Techne, Minneapolis, MN, USA), and assessed them in CSF and serum of symptomatic patients with probable or definite CNS NS (01/2011–02/2023) with gadolinium enhancement and/or CSF pleocytosis. Patients with multiple sclerosis, primary CNS lymphoma, aquaporin‐4 immunoglobulin G positivity, non‐inflammatory disorders, and healthy individuals were used as controls.

Results

A total of 32 NS patients (59% women; median age, 59 years [19–81]) were included; concurrent sera were available in 12. CSF controls consisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin‐4 immunoglobulin G positive, and 34 patients with non‐inflammatory disorders. Gadolinium enhancement was present in 31 of 32 NS patients, and CSF pleocytosis in 27 of 32 (84%). CSF IL‐2, IL‐6, IL‐10, IL‐13, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and TNF‐alpha levels were significantly higher in NS patients compared with non‐inflammatory controls ( p ≤ 0.02); elevations were more common in CSF than serum. Concurrent elevation of IL‐6, CXCL9, CXCL10, GM‐CSF, interferon‐gamma, and TNF‐alpha was present in 18 of 32 NS patients, but only in 1 control. Elevated IL‐6, IL‐10, IL‐13, CXCL9, CXL10, GM‐CSF, and TNF‐alpha associated with measures of disease activity.

Interpretation

NS CSF cytokine/chemokine profiles suggest T cell (mainly T helper cell type 1), macrophage, and B‐cell involvement. These signatures aid in NS diagnosis, indicate disease activity, and suggest therapeutic avenues. ANN NEUROL 2024;96:704–714

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisCentral Nervous System DiseasesCytokinesHumansFemaleMaleMiddle AgedAdultCase-Control StudiesAgedChemokinesBiomarkersDiagnosis, Differential

Substanzen

CytokinesChemokinesBiomarkers

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
  • Roche Product Development-Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland.

ORCID-Profile: Georgios Mangioris, Sean J Pittock, Divyanshu Dubey, Eoin P Flanagan, Sebastian A Lopez-Chiriboga, Andrew McKeon, W Oliver Tobin, Michel Toledano, Anastasia Zekeridou

Förderung

  • NINDS NIH HHS
  • Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic
  • Roche
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mangioris, G., Pittock, S. J., Yang, B., Fryer, J. P., Harmsen, W. S., Dubey, D., Flanagan, E. P., Lopez-Chiriboga, S. A., McKeon, A., Mills, J. R., Vodopivec, I., Tobin, W. O., Toledano, M., Aksamit, A. J., & Zekeridou, A. (2024). Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights. Annals of Neurology, 96(4), 704-714. https://doi.org/10.1002/ana.27024

Vancouver

Mangioris G, Pittock SJ, Yang B, Fryer JP, Harmsen WS, Dubey D, et al. Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights. Annals of Neurology. 2024;96(4):704-714. doi:10.1002/ana.27024

BibTeX
@article{Mangioris2024,
  author = {Mangioris, Georgios and Pittock, Sean J and Yang, Binxia and Fryer, James P and Harmsen, William S and Dubey, Divyanshu and Flanagan, Eoin P and Lopez-Chiriboga, Sebastian A and McKeon, Andrew and Mills, John R and Vodopivec, Ivana and Tobin, W Oliver and Toledano, Michel and Aksamit, Allen J and Zekeridou, Anastasia},
  title = {Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights},
  journal = {Annals of Neurology},
  year = {2024},
  volume = {96},
  number = {4},
  pages = {704--714},
  doi = {10.1002/ana.27024}
}
Kostenlos starten →